百时美施贵宝 ASCO2021.pdf

ASCO 2021 Investor Presentation June 8, 2021 Forward Looking Statement This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Not for Product Promotional Use 2 ASCO 2021 Samit Hirawat Executive VP Chief Medical Officer Global Drug Development Not for Product Promotional Use 3 BMS continues to advance its leadership in Oncology •Only company with three I-O agents: Opdivo, Yervoy Relatlimab* • Broad program across approaches, tumors, and stages of disease What we’ve learned at ASCO 2021: —Neo-adjuvant NSCLC (CM-816): following positive pCR results, favorable surgical outcomes post treatment GI cancer: favorable data with CM-648 complements upper GI program Dual I-O (Opdivo + Yervoy): continued long-term survival  Relatlimab: clinically meaningful